Side-by-side · Research reference
GHRP-6vsPNC-27
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1HUMAN-REVIEWED10/36 cited
BAnimal-StrongHUMAN-REVIEWED18/41 cited
GHRP-6
Hexapeptide GHRP · Strong appetite stimulant
SQ · Multiple sites · 1–3×/day
PNC-27
p53-HDM-2 Peptide · Membrane-Targeting
In vitro / Pre-clinical only
01Mechanism of Action
Parameter
GHRP-6
PNC-27
Primary target
Ghrelin receptor (GHS-R1a)Bowers 1990
Membrane-bound HDM-2 protein on cancer cell surfaceSarafraz-Yazdi 2022Krzesaj 2024
Pathway
GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002
PNC-27 binds to membrane HDM-2 1-109 domain → transmembrane pore formation → rapid necrosis (poptosis)Pincus 2024Krzesaj 2024
Downstream effect
GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002
Immediate cell lysis and extrusion of intracellular contents; secondary mitochondrial membrane disruptionPincus 2024Krzesaj 2024
Feedback intact?
—
N/A — cytotoxic mechanism, not signaling modulation
Origin
Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990
Chimeric design: p53 transactivating domain (12-26) fused to penetratin CPP sequenceSarafraz-Yazdi 2022
Antibody development
—
—
02Dosage Protocols
Parameter
GHRP-6
PNC-27
Frequency
1–3× per day
—
Lower / starter dose
50 mcg per dose
—
Duration
8–12 weeks on / 4 off
—
Reconstitution
Bacteriostatic water
—
Timing
Pre-meal preferred for appetite support
—
Clinical status
—
Pre-clinical only — no human trials
In vitro and animal model data only.
In vitro concentrations
—
10–100 μM range
Effective concentrations in cell culture studies.
Shorter analogue
—
PNC-28 (28 AA variant)
Retains HDM-2 binding and cytotoxic activity.
03Metabolic / Fat Loss Evidence
Parameter
GHRP-6
PNC-27
Fat loss mechanism
—
None — cytotoxic anticancer agent
04Side Effects & Safety
Parameter
GHRP-6
PNC-27
Hunger
Pronounced — defining feature vs ipamorelin
—
Cortisol elevation
Mild
—
Prolactin elevation
Mild
—
Injection site reaction
Mild
—
Cancer risk
Contraindicated in active malignancy
—
Pregnancy / OB
Avoid
—
Human safety data
—
None available — no human trials conducted
Normal cell selectivity
—
In vitro: no cytotoxicity to normal cells (MCF-10-2A, peripheral blood mononuclear cells)Sarafraz-Yazdi 2010Thadi 2020
Normal cells express minimal membrane HDM-2.
Cancer cell specificity
—
Depends on membrane HDM-2 expression levels
Ovarian cancer lines with low membrane HDM-2 showed <30% necrosis.
Mitochondrial effects
—
Secondary mitochondrial membrane disruption in cancer cells
Absolute Contraindications
GHRP-6
- ·Active malignancy
- ·Pregnancy / breastfeeding
PNC-27
- ·Human use — no clinical trials or safety data
Relative Contraindications
GHRP-6
- ·Severe insulin resistance (appetite-driven caloric load)
PNC-27
—05Administration Protocol
Parameter
GHRP-6
PNC-27
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
PNC-27 has not been tested in human subjects. All data derive from in vitro cancer cell line studies and limited animal models. No approved clinical formulation, dosing protocol, or safety profile exists.Pincus 2024
2. Injection site
SQ — abdomen. Rotate sites.
In vitro studies used 10–100 μM PNC-27 dissolved in cell culture medium. Peptide was added directly to cancer cell cultures (pancreatic, breast, colon, ovarian, leukemia lines) and incubated for 24–72 hours.
3. Timing
Pre-meal for appetite support; pre-sleep for GH alignment.
Dual-labeled PNC-27 (green on N-terminus, red on C-terminus) demonstrated intact peptide binding to cancer cell membranes with combined yellow fluorescence at 30 minutes, persisting during cell lysis.Sookraj 2010
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Cytotoxicity correlates directly with membrane HDM-2 expression levels. Blocking HDM-2's p53-binding domain (1-109) with monoclonal antibodies prevents PNC-27-induced necrosis.
5. Needle
29–31G, 4–8 mm insulin syringe.
—